PBYI — Puma Biotechnology Share Price
0.000.00%
Last trade - 00:00- $241.52m
- $245.23m
- $235.64m
- 64
- 70
- 70
- 76
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 21.56 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -42.46% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.52 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 16.81 | ||
| Price to Sales | 1.02 | ||
| EV to EBITDA | 5.55 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 24.89% | ||
| Return on Equity | 57.54% | ||
| Operating Margin | 13.85% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 272.26 | 225.11 | 253.16 | 228.03 | 235.64 | 219.23 | 217.03 | -1.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +158.87 | -44.28 | -35 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
Directors
- Alan Auerbach CHM (51)
- Maximo Nougues CFO (52)
- Douglas Hunt SVP (56)
- Jeff Ludwig OTH (55)
- Jay Moyes LED (67)
- Allison Dorval DRC (46)
- Michael Miller IND (64)
- Adrian Senderowicz IND (57)
- Brian Stuglik IND (62)
- Troy Wilson IND (52)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 15th, 2010
- Public Since
- March 21st, 2012
- No. of Shareholders
- 9
- No. of Employees
- 185
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 48,207,162
- Address
- 10880 Wilshire Blvd., Suite 2150, LOS ANGELES, 90024
- Web
- https://www.pumabiotechnology.com/
- Phone
- +1 4242486500
- Contact
- Mariann Ohanesian
- Auditors
- KPMG LLP
Upcoming Events for PBYI
Q1 2024 Puma Biotechnology Inc Earnings Call
Puma Biotechnology Inc Annual Shareholders Meeting
Q2 2024 Puma Biotechnology Inc Earnings Release
Similar to PBYI
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Puma Biotechnology share price?
As of Today at 19:17 UTC, shares in Puma Biotechnology are trading at $5.01. This share price information is delayed by 15 minutes.
How has the Puma Biotechnology share price performed this year?
Shares in Puma Biotechnology last closed at $5.01 and the price had moved by +88.35% over the past 365 days. In terms of relative price strength the Puma Biotechnology share price has outperformed the S&P500 Index by +56.73% over the past year.
What are the analyst and broker recommendations for Puma Biotechnology?
The overall consensus recommendation for Puma Biotechnology is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Puma Biotechnology dividend yield?
Puma Biotechnology does not currently pay a dividend.
Does Puma Biotechnology pay a dividend?
Puma Biotechnology does not currently pay a dividend.
When does Puma Biotechnology next pay dividends?
Puma Biotechnology does not currently pay a dividend.
How do I buy Puma Biotechnology shares?
To buy shares in Puma Biotechnology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Puma Biotechnology?
As of the previous close price of $5.01, shares in Puma Biotechnology had a market capitalisation of $241.52m.
Where are Puma Biotechnology shares listed?
Here are the trading details for Puma Biotechnology:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PBYI
What kind of share is Puma Biotechnology?
Based on an overall assessment of its quality, value and momentum Puma Biotechnology is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Puma Biotechnology share price forecast for 2024?
The analyst consensus target price for shares in Puma Biotechnology is $4.33. That is 13.57% below the last closing price of $5.01.
Analysts covering Puma Biotechnology currently have a consensus Earnings Per Share (EPS) forecast of $0.26 for the next financial year.
What is the trend in the Puma Biotechnology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Puma Biotechnology. Over the past six months, its share price has outperformed the S&P500 Index by +84.93%.
As of the last closing price of $5.01, shares in Puma Biotechnology were trading +21.33% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Puma Biotechnology PE Ratio?
The Puma Biotechnology PE ratio based on its reported earnings over the past 12 months is 21.56. The shares last closed at $5.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Puma Biotechnology?
Puma Biotechnology's management team is headed by:
- Alan Auerbach - CHM
- Maximo Nougues - CFO
- Douglas Hunt - SVP
- Jeff Ludwig - OTH
- Jay Moyes - LED
- Allison Dorval - DRC
- Michael Miller - IND
- Adrian Senderowicz - IND
- Brian Stuglik - IND
- Troy Wilson - IND